Brokerages Set argenx SE (NASDAQ:ARGX) Price Target at $630.42

argenx SE (NASDAQ:ARGX) has been given a consensus recommendation of “Moderate Buy” by the twenty-three ratings firms that are currently covering the company, Marketbeat reports. Three analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $630.42.

ARGX has been the topic of several analyst reports. William Blair upgraded argenx from a “market perform” rating to an “outperform” rating in a report on Friday, November 1st. Evercore ISI raised their price target on shares of argenx from $675.00 to $706.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. Deutsche Bank Aktiengesellschaft downgraded shares of argenx from a “buy” rating to a “hold” rating in a research report on Friday, October 4th. Wells Fargo & Company boosted their price target on argenx from $547.00 to $639.00 and gave the company an “overweight” rating in a report on Friday, November 1st. Finally, JMP Securities boosted their price target on argenx from $497.00 to $606.00 and gave the stock a “market outperform” rating in a research report on Friday, November 1st.

argenx Stock Performance

Shares of NASDAQ:ARGX opened at $616.55 on Thursday. The stock has a 50-day simple moving average of $565.73 and a 200-day simple moving average of $496.24. The stock has a market capitalization of $37.22 billion, a P/E ratio of -700.63 and a beta of 0.61. argenx has a 1 year low of $327.73 and a 1 year high of $620.28.

argenx (NASDAQ:ARGX) last issued its quarterly earnings data on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.10 by $1.29. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The business had revenue of $588.88 million during the quarter, compared to analyst estimates of $543.29 million. During the same period in the prior year, the company posted ($1.25) EPS. Analysts predict that argenx will post 2.2 earnings per share for the current year.

Institutional Trading of argenx

Several hedge funds have recently added to or reduced their stakes in ARGX. Profund Advisors LLC grew its position in argenx by 3.0% during the 2nd quarter. Profund Advisors LLC now owns 973 shares of the company’s stock worth $418,000 after purchasing an additional 28 shares during the last quarter. Raymond James Trust N.A. increased its position in argenx by 6.0% during the third quarter. Raymond James Trust N.A. now owns 495 shares of the company’s stock worth $268,000 after buying an additional 28 shares in the last quarter. Wealth Alliance raised its position in shares of argenx by 4.8% in the second quarter. Wealth Alliance now owns 628 shares of the company’s stock valued at $270,000 after buying an additional 29 shares during the last quarter. GAMMA Investing LLC increased its stake in argenx by 51.3% in the second quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock valued at $51,000 after purchasing an additional 40 shares during the last quarter. Finally, Hantz Financial Services Inc. lifted its holdings in shares of argenx by 8.9% during the 3rd quarter. Hantz Financial Services Inc. now owns 528 shares of the company’s stock worth $286,000 after acquiring an additional 43 shares during the period. Institutional investors and hedge funds own 60.32% of the company’s stock.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.